Icosavax
Public CompanyIcosavax develops virus-like particle vaccines targeting respiratory viruses such as RSV, hMPV, and COVID-19. Its platform uses computational protein design and virus-like particle scaffolds to create experimental vaccines intended to be shelf-stable and advance to clinical trials.
Facts
- HQ
- Seattle
- Sectors
- Biotechnology, Vaccines, Life Sciences
- Status
- Public Company
- Stage
- Public
- Members see funding amounts. .
Is this your organization? Claim it
Innovation Journeys: Stories of Invention & Discovery at UW - Episode 3: Icosavax
(https://comotion.uw.edu) Join UW vice provost for Innovation & CoMotion director François Baneyx as he speaks with Dr. Neil King, Co-founder of UW spinoff Icosavax (https://www.icosavax.com/) and Assistant Professor, Institute of Protein Design, about his commercialization journey and how CoMotion supported it through funding, resources, programs and more.
People
-
Neil King Co-founder